115 related articles for article (PubMed ID: 22843495)
1. Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle attenuation in pancreatic carcinoma cells.
Giessrigl B; Krieger S; Rosner M; Huttary N; Saiko P; Alami M; Messaoudi S; Peyrat JF; Maciuk A; Gollinger M; Kopf S; Kazlauskas E; Mazal P; Szekeres T; Hengstschläger M; Matulis D; Jäger W; Krupitza G
Hum Mol Genet; 2012 Nov; 21(21):4615-27. PubMed ID: 22843495
[TBL] [Abstract][Full Text] [Related]
2. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.
Arlander SJ; Eapen AK; Vroman BT; McDonald RJ; Toft DO; Karnitz LM
J Biol Chem; 2003 Dec; 278(52):52572-7. PubMed ID: 14570880
[TBL] [Abstract][Full Text] [Related]
3. Differential roles for checkpoint kinases in DNA damage-dependent degradation of the Cdc25A protein phosphatase.
Jin J; Ang XL; Ye X; Livingstone M; Harper JW
J Biol Chem; 2008 Jul; 283(28):19322-8. PubMed ID: 18480045
[TBL] [Abstract][Full Text] [Related]
4. Short 42 degrees C heat shock induces phosphorylation and degradation of Cdc25A which depends on p38MAPK, Chk2 and 14.3.3.
Madlener S; Rosner M; Krieger S; Giessrigl B; Gridling M; Vo TP; Leisser C; Lackner A; Raab I; Grusch M; Hengstschläger M; Dolznig H; Krupitza G
Hum Mol Genet; 2009 Jun; 18(11):1990-2000. PubMed ID: 19289404
[TBL] [Abstract][Full Text] [Related]
5. Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.
Demidova AR; Aau MY; Zhuang L; Yu Q
J Biol Chem; 2009 Feb; 284(7):4132-9. PubMed ID: 19060337
[TBL] [Abstract][Full Text] [Related]
6. Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.
Mayer P; Harjung A; Breinig M; Fischer L; Ehemann V; Malz M; Scherübl H; Britsch S; Werner J; Kern MA; Bläker H; Schirmacher P; Bergmann F
Endocr Relat Cancer; 2012 Jun; 19(3):217-32. PubMed ID: 22194440
[TBL] [Abstract][Full Text] [Related]
7. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine.
Morgan MA; Parsels LA; Parsels JD; Mesiwala AK; Maybaum J; Lawrence TS
Cancer Res; 2005 Aug; 65(15):6835-42. PubMed ID: 16061666
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells.
Kawamura D; Takemoto Y; Nishimoto A; Ueno K; Hosoyama T; Shirasawa B; Tanaka T; Kugimiya N; Harada E; Hamano K
Oncol Rep; 2017 Nov; 38(5):3238-3244. PubMed ID: 29048622
[TBL] [Abstract][Full Text] [Related]
9. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
10. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
Tse AN; Sheikh TN; Alan H; Chou TC; Schwartz GK
Mol Pharmacol; 2009 Jan; 75(1):124-33. PubMed ID: 18820127
[TBL] [Abstract][Full Text] [Related]
11. HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.
Ghadban T; Dibbern JL; Reeh M; Miro JT; Tsui TY; Wellner U; Izbicki JR; Güngör C; Vashist YK
Apoptosis; 2017 Mar; 22(3):369-380. PubMed ID: 27878398
[TBL] [Abstract][Full Text] [Related]
12. Hsp90 functions to balance the phosphorylation state of Akt during C2C12 myoblast differentiation.
Yun BG; Matts RL
Cell Signal; 2005 Dec; 17(12):1477-85. PubMed ID: 15935620
[TBL] [Abstract][Full Text] [Related]
13. HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells.
Adachi S; Yasuda I; Nakashima M; Yamauchi T; Yamauchi J; Natsume H; Moriwaki H; Kozawa O
Oncol Rep; 2010 Jun; 23(6):1709-14. PubMed ID: 20428829
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
15. Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism.
Uto K; Inoue D; Shimuta K; Nakajo N; Sagata N
EMBO J; 2004 Aug; 23(16):3386-96. PubMed ID: 15272308
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.
Pedersen KS; Kim GP; Foster NR; Wang-Gillam A; Erlichman C; McWilliams RR
Invest New Drugs; 2015 Aug; 33(4):963-8. PubMed ID: 25952464
[TBL] [Abstract][Full Text] [Related]
17. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation.
Yun BG; Matts RL
Exp Cell Res; 2005 Jul; 307(1):212-23. PubMed ID: 15922741
[TBL] [Abstract][Full Text] [Related]
19. Hypoxic suppression of the cell cycle gene CDC25A in tumor cells.
Hammer S; To KK; Yoo YG; Koshiji M; Huang LE
Cell Cycle; 2007 Aug; 6(15):1919-26. PubMed ID: 17671423
[TBL] [Abstract][Full Text] [Related]
20. The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM/ATR-mediated Chk1/2 cell cycle checkpoints.
Neumann J; Boerries M; Köhler R; Giaisi M; Krammer PH; Busch H; Li-Weber M
Int J Cancer; 2014 Apr; 134(8):1991-2002. PubMed ID: 24150948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
